Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel

• DOI: 10.21873/anticanres.13607
• Publication Date: 2019-07-31T23:15:19Z
• Authors: MEIKO NISHIMURA; TAKUMA ONOE; HIDEKI SAKAI; MINORI ARASE; SAYURI WATANABE; MISAO SOYAMA; KAZUKI HASHIMOTO; MAYUKO MIKI; KAORI TANE; KOICHI HIROKAGA; SHINTARO TAKAO; KOJI MATSUMOTO
• Keywords: Pegfilgrastim

Dose-dense doxorubicin and cyclophosphamide (ddAC) followed by dose-dense paclitaxel (ddP) (ddAC-P) has improved disease-free survival of patients with breast cancer. The aim this study was to evaluate the safety relative dose intensity (RDI) ddAC-P administered together pegfilgrastim.Between May 2015 Aug 2017, 44 were retrospectively reviewed; they 4 cycles ddAC, ddP. Pegfilgrastim (3.6 mg) in every cycle.The mean RDIs for ddAC-P, ddP 95.0%, 94.5%, 93.3%, respectively. prevalence high (≥85%) 90.9%, 84.1%, 88.6%, Seven 10 low experienced grade 1 or 2 fever.DdAC-P pegfilgrastim appears be feasible maintains RDI most Japanese Rapid evaluation proper management fever may prevent RDI.